Biotech -- CPRX# Stock
g*e
1 楼
Just read SA article below about CPRX -- the next ANRA:
http://seekingalpha.com/article/843531-3-speculative-biotech-st
Reasons to buy:
1. $6M stock offering just completed, that means someone just bought 4M
shares at $1.5
2. Catalyst event CPP-109 Phase IIb result due on or before 09/30
3. Huge market for CPP-109 the treatment of cocaine and methamphetamine
addiction and sensational impact to world on Drug addiction
4. FDA granted CPRX Fast Track status for CPP-109, that means NDA could be
submitted based on CPP-109
Cautions:
The company needs both time (years) and funding to have the drug Vigabatrin
in the market -- see below from the company filing.
'It is more likely that the FDA will require at least one Phase III trial
supported by the safety and efficacy data obtained from our Phase II(b)
clinical trial before they will file an NDA for CPP-109, even if the data
from our currently ongoing Phase II(b) clinical trial are compelling.
Further, even if the FDA files an NDA for CPP-109 based on the results of
our current Phase II(b) trial, we currently expect that we will not be in a
position to submit an NDA for CPP-109 until August 21, 2014. Finally, if the
FDA requires more than one Phase III clinical trial, our NDA submission
could be delayed even further. There can be no assurance that the data from
our ongoing Phase II(b) trial will be sufficiently compelling or that even
if such data are sufficiently compelling, that the FDA will file an NDA
submitted for CPP-109 based on the results of that trial'
Summary:
It is a strong buy at any price below $1.5 and will most likely over $2
before 09/30.
Enjoy trading! Welcome any comments!!
DISCLAIMER: This is intended for informational and entertainment use only
and should do your own DD before investing.
http://seekingalpha.com/article/843531-3-speculative-biotech-st
Reasons to buy:
1. $6M stock offering just completed, that means someone just bought 4M
shares at $1.5
2. Catalyst event CPP-109 Phase IIb result due on or before 09/30
3. Huge market for CPP-109 the treatment of cocaine and methamphetamine
addiction and sensational impact to world on Drug addiction
4. FDA granted CPRX Fast Track status for CPP-109, that means NDA could be
submitted based on CPP-109
Cautions:
The company needs both time (years) and funding to have the drug Vigabatrin
in the market -- see below from the company filing.
'It is more likely that the FDA will require at least one Phase III trial
supported by the safety and efficacy data obtained from our Phase II(b)
clinical trial before they will file an NDA for CPP-109, even if the data
from our currently ongoing Phase II(b) clinical trial are compelling.
Further, even if the FDA files an NDA for CPP-109 based on the results of
our current Phase II(b) trial, we currently expect that we will not be in a
position to submit an NDA for CPP-109 until August 21, 2014. Finally, if the
FDA requires more than one Phase III clinical trial, our NDA submission
could be delayed even further. There can be no assurance that the data from
our ongoing Phase II(b) trial will be sufficiently compelling or that even
if such data are sufficiently compelling, that the FDA will file an NDA
submitted for CPP-109 based on the results of that trial'
Summary:
It is a strong buy at any price below $1.5 and will most likely over $2
before 09/30.
Enjoy trading! Welcome any comments!!
DISCLAIMER: This is intended for informational and entertainment use only
and should do your own DD before investing.
